The European Commission has followed the advice of its human medicines committee and revoked the conditional marketing authorisation for Advanz Pharma's Ocaliva therapy for primary biliary
After two FDA rejections for non-alcoholic steatohepatitis (NASH) therapy obeticholic acid (OCA), Intercept Pharma has agreed to be taken over by Italian drugmaker Alfasig
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
